Iain Duncan

Biography

 Thirteen years in small and start-up pharma in executive positions; 20 years in various fortune 50 Corporations. Expert in virtual startups and multi-national outsourcing. Previously VP Manufacturing and Supply Chain Operations, with Horizon Therapeutics and directly managed Product Development, Manufacturing, Quality Control, Distribution and Logistics functions. Mr. Duncan formulated and developed Horizons’ lead product, DUEXIS© (patent pending co-author). Co- founder of NeuMedics, (Patent issued; co-author) co-founder of Corus Pharma Inc. (Patent issued; co-author) and served as its V.P. of Operations until Corus was acquired by Gilead in August 2006 for $365M. Mr. Duncan has been directly involved with the FDA approval of 3 drugs which are now commercial and the MAA approval of 2 drugs. Prior to Corus he worked with Chiron and was responsible for the integration of Pathogenesis into Chiron following its acquisition for $750M.

Research Interest

 Oncology